TechForce Robotics and Oncotelic Therapeutics showcased their joint development initiative at BIO International Convention 2026, highlighting autonomous robotics, AI technologies, and pharmaceutical manufacturing workflows designed for regulated environments.
OTCQB: NGTF
OTCQB: OTLC
During BIO International Convention 2026, attendees had the opportunity to learn about the Joint Development, Manufacturing, and Licensing Agreement between TechForce Robotics and Oncotelic Therapeutics. The collaboration combines autonomous robotics, AI technologies, and real-world pharmaceutical manufacturing environments to support the development of intelligent automation solutions for regulated facilities.
The following robotic platforms were showcased during BIO International Convention 2026 as part of the ongoing collaboration between TechForce Robotics and Oncotelic Therapeutics.
LIM-E™ supports internal supply transport and autonomous routing inside the laboratory. Designed to move approved laboratory supplies and properly contained materials between designated facility areas, LIM-E™ helps keep materials moving while laboratory teams stay focused on scientific and operational work.
Kebb-AI™ supports clean room operators through a robotic tablet interface with audio and voice-driven workflow capture. Built for gowned staff who may not be able to easily type or write while gloved, Kebb-i™ helps capture workflow inputs and support operator communication within controlled environments.
PUR-E™ supports clean room operations through mechanical handling and process automation within GMP-regulated environments. Designed to assist with approved handling workflows and repetitive operational steps, PUR-E™ helps reduce manual touchpoints and support consistency in critical laboratory processes.
A look back at BIO International Convention 2026, where TechForce Robotics and Oncotelic Therapeutics showcased autonomous robotic technologies and connected with professionals across the biopharma industry.
Visitors to Booth #1525 explored:
The technologies showcased during BIO International Convention 2026 are supported by ongoing development efforts within the SAPU Bio cGMP facility. Rather than serving solely as demonstration platforms, the robotic systems are being developed and evaluated in a regulated pharmaceutical manufacturing environment where electronic Batch Records (EBRs) and digital workflows play an important role in day-to-day operations.
LIM-E™ is currently deployed to support internal laboratory material transport throughout the facility. PUR-E™ is being developed for clean room operations involving approved material handling and repetitive process workflows. Kebb-ai™ complements these systems through a voice-enabled operator interface that allows gowned personnel to interact with manufacturing workflows using hands-free voice commands. Together, these initiatives represent the continued collaboration between TechForce Robotics and Oncotelic Therapeutics to advance intelligent automation within regulated pharmaceutical environments.
PDAOAI™ is Oncotelic's Knowledge Discovery platform, powered by Structural Intelligence. It folds 28 million papers into structure and identifies the root driver, not proximity. At BIO 2026, see it in two modes: Knowledge Discovery for drug discovery, and PDAOAI Robotics with PUR-E and LIM-E for AI-powered GMP manufacturing. Same engine. Two corpora. One booth.
Learn MoreExplore how Oncotelic Therapeutics and TechForce Robotics are applying a common
AI platform across drug discovery and GMP manufacturing.
Complete the form to access the platform cost breakdown.
Stay up to date on our latest announcements.
The technologies showcased during BIO International Convention 2026 are part of the ongoing collaboration between TechForce Robotics and Oncotelic Therapeutics.
Explore the joint development initiative to learn more about the robotic platforms, AI technologies, SAPU Bio deployment, and the latest project updates.
Interested in the technologies showcased at BIO International Convention 2026 or the ongoing collaboration between TechForce Robotics and Oncotelic Therapeutics?
Complete the form below and a member of our team will be in touch.
TechForce Robotics is an AI-enhanced service robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions across multiple industries. Through a vertically integrated platform combining proprietary robotics technology and real-world operating environments, TechForce is accelerating the adoption of automation from hospitality to high-value regulated industries including biopharma. TechForce Robotics is a wholly owned subsidiary of Nightfood Holdings Inc. (OTCQB: NGTF).
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company applying its proprietary PDAOAI engine to drug discovery and workflow automation. PDAOAI is the AI engine that, paired with TechForce’s robotics, is bringing intelligent automation to GMP biomanufacturing. Oncotelic advances novel therapeutics for cancer and immune disorders while commercializing its AI capabilities through partnerships like TechForce.
